scholarly journals Short-term Effect of Intravitreal Dexamethasone Implant on Diabetic Macular Edema with Epiretinal Membrane

2017 ◽  
Vol 2 (2) ◽  
pp. 68-75
Author(s):  
Donghyoun Noh ◽  
Jang Hwan Ahn ◽  
Junyeop Lee ◽  
Min Sagong
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Epiretinal Membrane ◽  
Term Effect ◽  
Dexamethasone Implant ◽  
Short Term ◽  
Short Term Effect ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone

scholarly journals Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane

2018 ◽  
Vol 62 (3) ◽  
pp. 212-216 ◽  
Author(s):  
Ashraf Khorasani Maryam ◽  
Mohammadi Tafgeh ◽  
Motallebi Mahmoud ◽  
Anvari Pasha ◽  
Sedaghat Ahad ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Epiretinal Membrane ◽  
Intravitreal Bevacizumab ◽  
Term Effect ◽  
Short Term ◽  
Short Term Effect

scholarly journals Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Antoine Herbaut ◽  
Franck Fajnkuchen ◽  
Lise Qu-Knafo ◽  
Sylvia Nghiem-Buffet ◽  
Bahram Bodaghi ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Retinal Thickness ◽  
Dexamethasone Implant ◽  
Short Term ◽  
Intravitreal Dexamethasone Implant ◽  
Refractory Diabetic Macular Edema ◽  
The Mean ◽  
Intravitreal Dexamethasone ◽  
Anatomical Outcomes

Purpose. To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. Methods. We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. Results. Twenty-five eyes were included. Before switching to aflibercept, 23 eyes received a median of 9.5 ranibizumab, and among them, 6 eyes received one dexamethasone implant after ranibizumab and 2 eyes received only one dexamethasone implant. Baseline VA, before any IVI, was 52.9 ± 16.5 letters, and preswitch VA was 57.1 ± 19.6 letters. The mean VA gain was +8 letters (p=0.01) between preswitch and M6. The mean central retinal thickness was 470.8 ± 129.9 μm before the switch and 303.3 ± 59.1 μm at M6 (p=0.001). Conclusion. Switching to aflibercept in refractory DME results in significant functional and anatomical improvement. The study was approved by the France Macula Federation ethical committee (FMF 2017-138).

Sign in / Sign up

Export Citation Format

Share Document